| Field | Specification |
|---|---|
| Mfr No | |
| Species |
FTC-133 is a human follicular thyroid carcinoma cell line derived from a lymph node metastasis. It is widely used to investigate the mechanisms underlying thyroid cancer progression, resistance to therapies, and gene expression changes associated with tumor biology. This cell line has been employed to study treatment responses in differentiated thyroid cancer (DTC) models, especially those linked to drug resistance and apoptosis pathways. Research involving FTC-133 has revealed its sensitivity to various inhibitors targeting DNA damage response pathways, such as the ATR inhibitor BAY 1895344, which can arrest growth, induce apoptosis, and enhance therapeutic outcomes when combined with tyrosine kinase inhibitors.
FTC-133 cells have also been significant in understanding multidrug resistance mechanisms. For example, this cell line demonstrates resistance to doxorubicin, associated with the overexpression of P-glycoprotein (P-gp) and interactions with the CD47 receptor. These factors contribute to reduced drug uptake and diminished apoptosis through pathways involving the JNK signaling cascade. The modulation of these resistance mechanisms has been studied by inhibiting P-gp, which restores sensitivity to doxorubicin. Such findings underscore the role of FTC-133 in exploring targeted therapies and resistance pathways, informing the development of more effective treatment regimens for thyroid cancers.
—
- Protein expression: Expression of 5' - Deiodinase Type I
- Mutational profile: Mutation: FLCN, p.His429Thrfs*39 (c.1285delC), homozygous Mutation: MSH6, p.Lys1045fs (c.3135delG), homozygous Mutation: NF1, p.Cys167Ter (c.501T>A), homozygous Mutation: PTEN, p.Arg130Ter (c.388C>T), homozygous Mutation: TERT, c.1-124C>T (c.228C>T) (C228T), homozygous Mutation: TP53, p.Arg273His (c.818G>A), homozygous
- cultureMedium: DMEM:Ham's F12 (1:1), w: 3.1 g/L Glucose, w: 2.5 mM L-Glutamine, w: 15 mM HEPES, w: 0.5 mM Sodium pyruvate, w: 1.2 g/L NaHCO3 (Cytion article number 820400a)
- supplements: Supplement the medium with 10% FBS
- dissociationReagent: Accutase
- subculturing: Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium.
- seedingDensity: 1 - 5 x 104 cells/cm2
- freezeMedium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.
10%
OFF
15%OFF
20%
OFF
$50
OFF
FREE
SAMPLE
